Suratadenoturev (OBP-301)

· Weill Medical College of Cornell University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Suratadenoturev (OBP-301), covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma [Phase 2]